Leerink partners maintained a Buy rating on United Therapeutics stock on July 28, 2025.
1 report, 1 independent
Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners maintained a Buy rating on United Therapeutics stock on July 28, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
-
Leerink partners
U.S. investment bank
Related events
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
Coverage
Newest first; wire copies grouped- Insider MonkeyLeerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now. In